Wojciech Kuban

Wojciech Kuban, is an Assistant Professor in the Department of Pharmacokinetics and Drug Metabolism at the Maj Institute of Pharmacology, Polish Academy of Sciences. His scientific profile encompasses biochemistry, molecular pharmacology, computational biopharmacy, mass spectrometry, proteomics, pharmacogenomics and biomarker research in neurological diseases. His core research expertise focuses on the application of LC-MS/MS techniques in experimental and translational pharmacology, drug metabolism studies, brain and liver cytochrome P450 biology, neuropharmacology and pharmacokinetics. Particular emphasis is placed on the integration of proteomic, genomic, pharmacogenomic, pharmacokinetic and clinical data using bioinformatic, computational and artificial-intelligence-based approaches. An important area of research interest is the identification of molecular mechanisms of drug action and biomarkers of central nervous system disorders. In this context, approaches based on high-resolution mass spectrometry, DIA proteomics, plasma, serum and cerebrospinal-fluid analysis, and multidimensional data interpretation are developed and applied in pharmacological and clinical research. Particular attention is given to the molecular stratification and differential characterization of neurological diseases, including amyotrophic lateral sclerosis. His research experience was gained in academic and biomedical research institutions in Poland, the United States, Sweden, Singapore and Australia, covering DNA metabolism and repair, enzymology, chromatin regulation, telomere biology and AAV-based gene-therapy platforms. This profile is complemented by biotechnology and pharmaceutical R&D experience, including management of contract research projects, method validation, technology transfer and delivery of studies in regulated, quality-controlled environments. His current scientific activity integrates experimental pharmacology, LC-MS/MS analytics, high-resolution proteomics, pharmacogenomics and computational biopharmacy. Its overarching aim is to develop integrated strategies for elucidating drug mechanisms, identifying biomarkers and enabling translational interpretation of molecular data in neurological diseases.